

# CITATION REPORT

List of articles citing

**Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis**

**DOI: 10.1001/jama.2015.4668**

**JAMA - Journal of the American Medical Association, 2015, 313, 1924-38.**

**Source:** <https://exaly.com/paper-pdf/62263412/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1025	Alzheimer's disease. <b>2015</b> , 1, 15056		755
1024	Subjective Memory Complaints in APOEε4 Carriers are Associated with High Amyloid-β Burden. <b>2016</b> , 49, 1115-22		40
1023	Zentraler Einfluss des Alters und Apolipoprotein-E-Genotyps. <b>2015</b> , 17, 12-12		
1022	Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. <b>2015</b> , 7, 75		38
1021	PET Amyloid-Beta Biomarkers Reveal Complexities in AD, Other Dementias. <b>2015</b> , 15, 1		
1020	Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. <b>2016</b> , 49, 271-6		19
1019	Aβ Clearance, "hub" of Multiple Deficiencies Leading to Alzheimer Disease. <b>2015</b> , 7, 200		13
1018	Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease. <b>2015</b> , 8, 47		26
1017	What is Normal Cognitive Aging? Evidence from Task-Based Functional Neuroimaging. <b>2015</b> , 2, 256-261		14
1016	Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. <b>2015</b> , 37, 1643-51.e3		11
1015	Biomarkers for Alzheimer's disease: a controversial topic. <b>2015</b> , 14, 781-783		8
1014	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1939-49	27.4	379
1013	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <b>2015</b> , 138, 3747-59		128
1012	Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?. <b>2015</b> , 11, 669-70		9
1011	[Stress and optimal ageing]. <b>2015</b> , 48, 524-8		
1010	Persistence of Aβ seeds in APP null mouse brain. <b>2015</b> , 18, 1559-61		45
1009	Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging. <b>2015</b> , 56, 1467		

1008	The APP A673T frequency differs between Nordic countries. <b>2015</b> , 36, 2909.e1-4	7
1007	Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE e4 Genotype. <b>2016</b> , 52, 849-61	43
1006	[Not Available]. <b>2016</b> , 19, 74-82	2
1005	Imaging Alzheimer's disease pathophysiology with PET. <b>2016</b> , 10, 79-90	21
1004	The New Criteria for Alzheimer's Disease - Implications for Geriatricians. <b>2016</b> , 19, 66-73	10
1003	Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention. <b>2016</b> , 50, 779-89	20
1002	Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis. <b>2016</b> , 8, 267	18
1001	Cognitive Intervention As an Early Non-pharmacological Strategy in Alzheimer's Disease: A Translational Perspective. <b>2016</b> , 8, 280	5
1000	Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <b>2016</b> , 11, e0146449	22
999	Cognitive impairment and stroke in elderly patients. <b>2016</b> , 12, 105-16	52
998	Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway. <b>2016</b> , 30, 8-14	2
997	Impairments of neural circuit function in Alzheimer's disease. <b>2016</b> , 371,	143
996	Pathological $\beta$ synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. <b>2016</b> , 79, 940-9	194
995	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. <b>2016</b> , 279, 576-91	48
994	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <b>2016</b> , 54, 383-95	31
993	ZiBu PiYin recipe prevents diabetes-associated cognitive decline in rats: possible involvement of ameliorating mitochondrial dysfunction, insulin resistance pathway and histopathological changes. <b>2016</b> , 16, 200	19
992	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <b>2016</b> , 8, 41	78
991	Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. <b>2016</b> , 22, 978-990	13

990	Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?. <b>2016</b> , 50, 645-58	9
989	Aquaporin-4 and Alzheimer's Disease. <b>2016</b> , 52, 391-402	25
988	Topographical APOE e4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis. <b>2016</b> , 54, 559-68	5
987	Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study. <b>2016</b> , 8, 55	11
986	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. <b>2016</b> , 51, 1085-97	10
985	Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and Amyloid imaging. <b>2016</b> , 5, 23-34	30
984	Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation. <b>2016</b> , 123, 421-4	21
983	White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. <b>2016</b> , 4, 18-27	48
982	Patterns of 11 C-PIB cerebral retention in mild cognitive impairment patients. <b>2016</b> , 35, 171-174	
981	Amyloid Imaging in Dementia and Related Disorders. <b>2016</b> , 89-102	
980	Patterns of 11C-PIB cerebral retention in mild cognitive impairment patients. <b>2016</b> , 35, 171-4	3
979	Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. <b>2016</b> , 16, 104	39
978	A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load. <b>2016</b> , 24, 804-13	57
977	Nuclear Imaging of Dementia. <b>2016</b> , 233-240	
976	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <b>2016</b> , 15, 673-684	979
975	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. <b>2016</b> , 15, 650-651	8
974	What are we willing to accept for preventing Alzheimer's disease? - Investigators' reply. <b>2016</b> , 15, 660-661	1
973	Individual estimates of age at detectable amyloid onset for risk factor assessment. <b>2016</b> , 12, 373-9	49

972	Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. <b>2016</b> , 25, 5148-5166	92
971	The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE. <b>2016</b> , 87, 473-80	81
970	Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. <b>2016</b> , 139, 324-332	18
969	Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. <b>2016</b> , 47, 2645-8	20
968	Assessing risk for preclinical $\beta$ amyloid pathology with , cognitive, and demographic information. <b>2016</b> , 4, 76-84	36
967	Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid. <b>2016</b> , 75, 918-924	34
966	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <b>2016</b> , 54, 287-95	50
965	Electroconvulsive therapy selectively enhances amyloid $\beta$ -42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. <b>2016</b> , 26, 1877-1884	13
964	Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells. <b>2016</b> , 113, E8187-E8196	98
963	Molecular imaging in the diagnosis of Alzheimer's disease and related disorders. <b>2016</b> , 172, 725-734	17
962	Feasibility and acceptance of simultaneous amyloid PET/MRI. <b>2016</b> , 43, 2236-2243	22
961	Neuroimaging Advances in Alzheimer's Disease. <b>2016</b> , 263-282	0
960	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral $\beta$ amyloidosis. <b>2016</b> , 7, 10918	39
959	Diagnostic role of <sup>11</sup> C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnesic and nonamnesic mild cognitive impairment patients. <b>2016</b> , 37, 1189-96	6
958	PET Imaging as a Diagnostic Tool in Alzheimer's Disease. <b>2016</b> , 199-213	
957	Genetic variants in Alzheimer disease - molecular and brain network approaches. <b>2016</b> , 12, 413-27	71
956	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. <b>2016</b> , 139, 2261-74	27
955	Ion channel regulation by $\beta$ secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. <b>2016</b> , 10, 365-378	18

954	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. <b>2016</b> , 22, 285-8	5
953	Impaired fasting glucose is associated with increased regional cerebral amyloid. <b>2016</b> , 44, 138-142	21
952	Olfactory memory in the old and very old: relations to episodic and semantic memory and APOE genotype. <b>2016</b> , 38, 118-126	29
951	Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671N1L)/PSEN1(Bxon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology. <b>2016</b> , 21, 1099-111	8
950	Greater memory impairment in dementing females than males relative to sex-matched healthy controls. <b>2016</b> , 38, 527-33	29
949	[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets]. <b>2016</b> , 87, 1163-1174	5
948	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <b>2016</b> , 46, 57-87	11
947	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <b>2016</b> , 15, 56-64	82
946	Alzheimer's disease biomarker states. <b>2016</b> , 15, 25-6	2
945	Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology. <b>2016</b> , 57, 297-302	8
944	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <b>2016</b> , 12, 292-323	832
943	Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. <b>2016</b> , 86, 1128-35	55
942	The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. <b>2016</b> , 30, 53-69	33
941	Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis - What do we need to know?. <b>2016</b> , 41, 153-71	74
940	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. <b>2016</b> , 37, 663-72	35
939	Neuroimaging biomarkers in Alzheimer's disease and other dementias. <b>2016</b> , 30, 4-16	27
938	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <b>2016</b> , 15, 455-532	921
937	Alzheimer's disease. <b>2016</b> , 388, 505-17	1720

936 Neuroimaging in the assessment and treatment of dementias. **2016**, 22, 63-67

935 Can physical exercise in old age improve memory and hippocampal function?. **2016**, 139, 662-73 168

934 Blood metabolite markers of neocortical amyloid- $\beta$  burden: discovery and enrichment using candidate proteins. **2016**, 6, e719 22

933 Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease. **2016**, 34, 681-707 11

932 Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. **2016**, 139, 1551-67 570

931 Propagation of A $\beta$  pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. **2016**, 131, 5-25 54

930 Excessive variability in systolic blood pressure that is self-measured at home exacerbates the progression of brain white matter lesions and cognitive impairment in the oldest old. **2016**, 39, 245-53 32

929 Gray matter network disruptions and amyloid beta in cognitively normal adults. **2016**, 37, 154-160 41

928 Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. **2016**, 86, 50-8 48

927 Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. **2017**, 322, 280-287 19

926 Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. **2017**, 88, 569-576 28

925 Cognitive impairment and decline in cognitively normal older adults with high amyloid- $\beta$  meta-analysis. **2017**, 6, 108-121 96

924 Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure. **2017**, 39, 753-767 18

923 Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. **2017**, 56, 543-555 7

922 Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. **2017**, 31, 147-168 108

921 Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. **2017**, 13, 148-159 79

920 Unbiased estimates of cerebrospinal fluid  $\beta$ amyloid 1-42 cutoffs in a large memory clinic population. **2017**, 9, 8 35

919 APOE $\epsilon$ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. **2017**, 57, 411-422 9

918	Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. <b>2017</b> , 62, 203-211	63
917	Vascular Cognitive Impairment. <b>2017</b> , 120, 573-591	246
916	The role of APOE on lipid homeostasis and inflammation in normal brains. <b>2017</b> , 58, 1493-1499	64
915	Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance. <b>2017</b> , 9, 6	15
914	Emerging biomarkers and screening for cognitive frailty. <b>2017</b> , 29, 1075-1086	31
913	Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study. <b>2017</b> , 54, 94-99	35
912	Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology. <b>2017</b> , 90, 12-20	23
911	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 1443-1450	27.4 299
910	Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No?. <b>2017</b> , 58, 323-335	9
909	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <b>2017</b> , 74, 718-726	87
908	Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review. <b>2017</b> , 58, 789-801	72
907	Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. <b>2017</b> , 27, 305-325	54
906	Imaging the ageing brain: identifying early disease or opening Pandora's box?. <b>2017</b> , 16, 411-413	2
905	Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults. <b>2017</b> , 32, 320-328	10
904	Circadian Rhythms in AD pathogenesis: A Critical Appraisal. <b>2017</b> , 3, 85-92	19
903	The neurology of ageing: what is normal?. <b>2017</b> , 17, 172-182	20
902	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <b>2017</b> , 58, 939-950	48
901	Re-imagining Alzheimer's disease - the diminishing importance of amyloid and a glimpse of what lies ahead. <b>2017</b> , 143, 432-444	57



900	Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. <b>2017</b> , 23, 41-51	10
899	Alterations in the Balance of Amyloid- $\beta$ Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <b>2017</b> , 57, 1281-1291	4
898	Epileptic activity in Alzheimer's disease: causes and clinical relevance. <b>2017</b> , 16, 311-322	230
897	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <b>2017</b> , 52, 167-182.e1	51
896	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <b>2017</b> , 52, 214-227	52
895	Convergent and divergent effects of apolipoprotein E $\epsilon 4$ and $\epsilon 2$ alleles on amygdala functional networks in nondemented older adults. <b>2017</b> , 54, 31-39	9
894	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <b>2017</b> , 60, 1025-1034	21
893	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <b>2017</b> , 44, 2239-2248	9
892	Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. <b>2017</b> , 100, 45-53	17
891	Task-evoked pupil dilation and BOLD variance as indicators of locus coeruleus dysfunction. <b>2017</b> , 97, 60-69	26
890	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <b>2017</b> , 82, 706-718	99
889	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <b>2017</b> , 89, 2039-2048	13
888	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. <b>2017</b> , 59, 603-614	35
887	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <b>2017</b> , 74, 1481-1491	58
886	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <b>2017</b> , 60, 1119-1128	21
885	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <b>2017</b> , 60, 1387-1395	15
884	Reduced age-associated brain changes in expert meditators: a multimodal neuroimaging pilot study. <b>2017</b> , 7, 10160	26
883	Small-molecule PET Tracers for Imaging Proteinopathies. <b>2017</b> , 47, 553-575	65

882	Assessment of amyloid $\beta$ in pathologically confirmed frontotemporal dementia syndromes. <b>2017</b> , 9, 10-20	29
881	Strategies for Preventing Cognitive Decline in Healthy Older Adults. <b>2017</b> , 62, 754-760	15
880	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <b>2017</b> , 117, 591-602	57
879	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound A $\beta$ oligomers. <b>2017</b> , 28, 2623-2636	59
878	Brain amyloid PET interpretation approaches: from visual assessment in the clinic to quantitative pharmacokinetic modeling. <b>2017</b> , 5, 561-573	3
877	ApoE4 Accelerates Early Seeding of Amyloid Pathology. <b>2017</b> , 96, 1024-1032.e3	157
876	Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis. <b>2017</b> , 49, 165-173	8
875	Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. <b>2017</b> , 89, 2438-2446	25
874	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. <b>2017</b> , 60, 1641-1652	13
873	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. <b>2017</b> , 37, 12263-12271	28
872	Beitrag peripherer bildgebender Verfahren zur Diagnose neuromuskulärer Erkrankungen. <b>2017</b> , 39, 198-216	
871	Dissociable Effects of Aging and Mild Cognitive Impairment on Bottom-Up Audiovisual Integration. <b>2017</b> , 59, 155-167	10
870	A clinicopathological approach to the diagnosis of dementia. <b>2017</b> , 13, 457-476	138
869	Chemically treated plasma A $\beta$ s a potential blood-based biomarker for screening cerebral amyloid deposition. <b>2017</b> , 9, 20	38
868	Communicating mild cognitive impairment diagnoses with and without amyloid imaging. <b>2017</b> , 9, 35	33
867	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. <b>2017</b> , 58, 491-505	36
866	Molecular Imaging of Extrapyrarnidal Movement Disorders. <b>2017</b> , 47, 18-30	3
865	Amyloid pet in primary progressive aphasia: case series and systematic review of the literature. <b>2017</b> , 264, 121-130	16

864	Lesion Topography and Microscopic White Matter Tract Damage Contribute to Cognitive Impairment in Symptomatic Carotid Artery Disease. <b>2017</b> , 282, 502-515	15
863	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <b>2017</b> , 13, 205-216	358
862	Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. <b>2017</b> , 95, 943-972	192
861	H-MRS metabolites and rate of Amyloid accumulation on serial PET in clinically normal adults. <b>2017</b> , 89, 1391-1399	12
860	Diagnosis on Mild Cognitive Impairment Patients for Alzheimer Disease with Missing Data. <b>2017</b> ,	
859	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <b>2017</b> , 140, 2286-2294	94
858	Tau Proteins. <b>2017</b> , 145-160	1
857	Biomarkers for Alzheimer's Disease Diagnosis. <b>2017</b> , 14, 1149-1154	91
856	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. <b>2017</b> , 9, 77	34
855	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <b>2017</b> , 11, 281	47
854	Detecting At-Risk Alzheimer's Disease Cases. <b>2017</b> , 60, 97-105	23
853	Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. <b>2017</b> , 17, 210	9
852	Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. <b>2017</b> , 14, 193	9
851	On the path to 2025: understanding the Alzheimer's disease continuum. <b>2017</b> , 9, 60	197
850	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. <b>2017</b> , 9, 99	3
849	Aging and Alzheimer's Disease. <b>2017</b> , 311-340	
848	Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. <b>2016</b> , 6, 465-476	5
847	APOE $\epsilon$ specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease. <b>2017</b> , 9, 964-985	26

846	Sleep, Adenosine, and Neurodegeneration. <b>2017</b> , 111-130	
845	The emerging role of PET imaging in dementia. <b>2017</b> , 6, 1830	36
844	Imaging of Brain Amyloid Load in Early Alzheimer's Disease. <b>2018</b> , 149-156	
843	Positron Emission Tomography (PET) Imaging. <b>2018</b> , 164-187	
842	Midlife insulin resistance, genotype, and late-life brain amyloid accumulation. <b>2018</b> , 90, e1150-e1157	27
841	Proximity to Parental Symptom Onset and Amyloid Burden in Sporadic Alzheimer Disease. <b>2018</b> , 75, 608-619	16
840	Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. <b>2018</b> , 43, 81-98	44
839	Moderating effect of $\beta$ on the relationship between sleep-wake cycle and brain $\beta$ amyloid. <b>2018</b> , 90, e1167-e1173	16
838	Cognitive and neuroimaging features and brain $\beta$ amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <b>2018</b> , 17, 335-346	113
837	One step towards dementia prevention. <b>2018</b> , 17, 294-295	2
836	Premature hippocampus-dependent memory decline in middle-aged females of a genetic rat model of depression. <b>2018</b> , 353, 242-249	5
835	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE $\epsilon$ genotype. <b>2018</b> , 141, 1828-1839	53
834	Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. <b>2018</b> , 4, 141-149	7
833	Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study. <b>2018</b> , 63, 861-869	24
832	Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults. <b>2018</b> , 62, 1759-1766	15
831	Neuropsychological Predictors of Long-Term (10 Years) Mild Cognitive Impairment Stability. <b>2018</b> , 62, 1703-1711	12
830	Amyloid blood biomarker detects Alzheimer's disease. <b>2018</b> , 10,	100
829	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <b>2018</b> , 14, 535-562	3155

828	Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. <b>2018</b> , 90, e1682-e1691	18
827	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasia. <b>2018</b> , 90, e1057-e1065	8
826	Capturing the Alzheimer's disease pathological cascade. <b>2018</b> , 17, 199-200	4
825	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. <b>2018</b> , 18, 167-177	65
824	The role of biomarkers and imaging in the clinical diagnosis of dementia. <b>2018</b> , 47, 641-643	19
823	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. <b>2018</b> , 62, 165-174	5
822	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. <b>2018</b> , 75, 582-590	166
821	Health Policy and Dementia. <b>2018</b> , 20, 4	5
820	Evidence-based Interpretation of Amyloid-PET Results: A Clinician's Tool. <b>2018</b> , 32, 28-34	21
819	Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. <b>2018</b> , 64, 68-75	15
818	Amyloid pathology in the progression to mild cognitive impairment. <b>2018</b> , 64, 76-84	17
817	Both hyper- and hypo-activation to cognitive challenge are associated with increased beta-amyloid deposition in healthy aging: A nonlinear effect. <b>2018</b> , 166, 285-292	16
816	Alzheimer's disease: An ignored condition. <b>2018</b> , 150, 432-433	2
815	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. <b>2017</b> , 7, 374-385	20
814	An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group. <b>2018</b> , 49, 9-16	38
813	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <b>2018</b> , 48, 3-9	22
812	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. <b>2018</b> , 75, 342-352	59
811	Altered structural network organization in cognitively normal individuals with amyloid pathology. <b>2018</b> , 64, 15-24	20

810	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. <b>2018</b> , 63, 887-897	11
809	Major or Mild Neurocognitive Disorder Due to Alzheimer Disease. <b>2018</b> , 369-401	
808	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <b>2018</b> , 75, 970-979	69
807	Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. <b>2018</b> , 90, 695-703	120
806	Effects of APOE- $\epsilon$ allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. <b>2018</b> , 14, 902-912	64
805	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment. <b>2018</b> , 64, S281-S287	5
804	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. <b>2018</b> , 64, S647-S657	5
803	Prevalence of the apolipoprotein E $\epsilon$ allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <b>2018</b> , 14, 913-924	36
802	Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and $\beta$ amyloid as an indicator of cognitive performance at high age. <b>2018</b> , 174, 308-316	37
801	Circular Inference in Dementia Diagnostics. <b>2018</b> , 63, 69-73	10
800	Memory decline accompanies subthreshold amyloid accumulation. <b>2018</b> , 90, e1452-e1460	80
799	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <b>2018</b> , 75, 738-745	32
798	Alzheimer mouse brain tissue measured by time resolved fluorescence spectroscopy using single- and multi-photon excitation of label free native molecules. <b>2018</b> , 11, e201600318	14
797	Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-e4 allele carriers aged 45-75: Results from the ALFA study. <b>2018</b> , 38, 250-261	17
796	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. <b>2018</b> , 10,	305
795	Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. <b>2018</b> , 62, 1403-1416	316
794	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <b>2018</b> , 19, 244-328	148
793	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. <b>2018</b> , 17, 452-464	83

792	Risk factors for amyloid positivity in older people reporting significant memory concern. <b>2018</b> , 80, 126-131	8
791	How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. <b>2018</b> , 33, 48-57	82
790	Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals. <b>2018</b> , 14, 601-609	163
789	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <b>2018</b> , 75, 84-95	94
788	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ -42 Analysis Results. <b>2018</b> , 64, 576-585	76
787	Associations Between Tau, $\beta$ Amyloid, and Cognition in Parkinson Disease. <b>2018</b> , 75, 227-235	36
786	Mixed emotions: What to do with patients who have lobar and deep hemorrhages on MRI?. <b>2018</b> , 90, 55-56	2
785	Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. <b>2018</b> , 135, 85-93	57
784	Added value of F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. <b>2018</b> , 14, 293-305	34
783	Exploring APOE genotype effects on Alzheimer's disease risk and amyloid $\beta$ burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. <b>2018</b> , 14, 634-643	21
782	Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. <b>2018</b> , 63, 140-151	20
781	Diagnostiek van de ziekte van Alzheimer. <b>2018</b> , 22, 172-179	
780	Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease. <b>2018</b> , 66, 1105-1116	12
779	Decoding the synaptic dysfunction of bioactive human AD brain soluble A $\beta$ o inspire novel therapeutic avenues for Alzheimer's disease. <b>2018</b> , 6, 121	28
778	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <b>2018</b> , 18, 289	15
777	Amyloid PET in neurodegenerative diseases with dementia. <b>2018</b> , 37, 397-406	
776	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <b>2018</b> , 10, 409	20
775	Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints. <b>2018</b> , 66, 1599-1608	3

774	Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the FundaciACE Healthy Brain Initiative (FACEHBI). <b>2018</b> , 10, 119	25
773	Prevalence of amyloid- $\beta$ pathology in distinct variants of primary progressive aphasia. <b>2018</b> , 84, 729-740	74
772	Abnormal CSF amyloid- $\beta$ 2 and tau levels in hip fracture patients without dementia. <b>2018</b> , 13, e0204695	14
771	Imaging the evolution and pathophysiology of Alzheimer disease. <b>2018</b> , 19, 687-700	194
770	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <b>2018</b> , 10, 100	30
769	Ageing, Cellular Senescence and Neurodegenerative Disease. <b>2018</b> , 19,	129
768	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <b>2018</b> , 18, 847-857	47
767	Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. <b>2018</b> , 24, 842-853	32
766	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <b>2018</b> , 141, 3233-3248	15
765	Early affective changes and increased connectivity in preclinical Alzheimer's disease. <b>2018</b> , 10, 471-479	19
764	Questions concerning the role of amyloid- $\beta$ in the definition, aetiology and diagnosis of Alzheimer's disease. <b>2018</b> , 136, 663-689	101
763	Prediction of Cerebral Amyloid With Common Information Obtained From Memory Clinic Practice. <b>2018</b> , 10, 309	14
762	The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. <b>2018</b> , 10,	68
761	Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1151-1162	27.4 173
760	Laboratory diagnostics in dementia. <b>2018</b> , 42, 121-130	1
759	Is intracranial volume a suitable proxy for brain reserve?. <b>2018</b> , 10, 91	23
758	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <b>2018</b> , 10, 75	24
757	The Association of Apolipoprotein E Gene Polymorphism With Cognitive Performance in Nondemented Polish Adults Aged 55 to 75. <b>2018</b> , 87, 124-140	2



756	"Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game. <b>2018</b> , 10, 53	13
755	Relationship Between Amyloid- $\beta$ Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <b>2018</b> , 65, 1313-1325	14
754	Chasing the start of sporadic Alzheimer's disease running in families. <b>2018</b> , 141, 1589-1591	2
753	Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. <b>2018</b> , 14, 981-988	67
752	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <b>2018</b> , 64, S633-S646	27
751	Profiling the Serum Protein Corona of Fibrillar Human Islet Amyloid Polypeptide. <b>2018</b> , 12, 6066-6078	28
750	A quantitative EEG and MRI analysis of intermittent temporal slowing in the elderly. <b>2018</b> , 3, 114-119	
749	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <b>2018</b> , 19, 406-416	37
748	From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. <b>2018</b> , 4, 243-251	7
747	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. <b>2018</b> , 82, 163-185	23
746	A new era for dementia epidemiology: Alzheimer's disease, hardening of arteries, or just old age?. <b>2018</b> , 33, 613-616	4
745	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <b>2018</b> , 14, 1313-1333	61
744	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <b>2018</b> , 10, 72	25
743	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <b>2018</b> , 5, 1037-1047	17
742	Personality and Dementia. <b>2018</b> , 83-110	
741	Association between vascular comorbidity and progression of Alzheimer's disease: a two-year observational study in Norwegian memory clinics. <b>2018</b> , 18, 120	18
740	Early-Life Cognitive Activity Is Related to Reduced Neurodegeneration in Alzheimer Signature Regions in Late Life. <b>2018</b> , 10, 70	11
739	Amyloid- $\beta$ , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <b>2018</b> , 10, 193	9

738	An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. <b>2018</b> , 12, 275	21
737	Sex differences in Alzheimer disease - the gateway to precision medicine. <b>2018</b> , 14, 457-469	280
736	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <b>2018</b> , 14, 1204-1215	40
735	Effects of APOE $\epsilon$ on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <b>2018</b> , 71, 81-90	8
734	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. <b>2018</b> , 71, 72-80	21
733	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <b>2018</b> , 10, 67	18
732	Addition of the A $\beta$ 2/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. <b>2018</b> , 10, 33	36
731	Longitudinal effects of aging on F-FDG distribution in cognitively normal elderly individuals. <b>2018</b> , 8, 11557	18
730	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <b>2018</b> , 70, 22-29	8
729	White matter microstructure is altered in cognitively normal middle-aged APOE- $\epsilon$ homozygotes. <b>2018</b> , 10, 48	27
728	Alzheimer's disease neuropathology may not predict functional impairment in HIV: a report of two individuals. <b>2018</b> , 24, 629-637	8
727	Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism. <b>2018</b> , 10, 84	15
726	Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification. <b>2018</b> , 20, 153-160	8
725	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. <b>2018</b> , 8, e01080	9
724	Increasing beta-amyloid deposition in cognitively healthy aging predicts nonlinear change in BOLD modulation to difficulty. <b>2018</b> , 183, 142-149	6
723	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <b>2018</b> , 10, 76	56
722	Amyloid PET in neurodegenerative diseases with dementia. <b>2018</b> , 37, 397-406	
721	Prevalence of major depressive disorder in older adults in China: A systematic review and meta-analysis. <b>2018</b> , 241, 297-304	29

720	Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. <b>2018</b> , 63, 1025-1033	4
719	Alzheimer's disease: An ignored condition. <b>2018</b> , 150, 432-433	1
718	Relationship between frailty and Alzheimer's disease biomarkers: A scoping review. <b>2018</b> , 10, 394-401	22
717	Preclinical Alzheimer's Disease: Implications for Refinement of the Concept. <b>2018</b> , 64, S213-S227	6
716	The use of cerebrospinal fluid in biomarker studies. <b>2017</b> , 146, 3-20	11
715	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <b>2018</b> , 70, 170-179	10
714	Regional times to equilibria and their impact on semi-quantification of [F]AV-1451 uptake. <b>2019</b> , 39, 2223-2232	5
713	Longitudinal Functional Brain Mapping in Supernormals. <b>2019</b> , 29, 242-252	14
712	The Ankle-Brachial Index Is Associated with Cerebral $\beta$ Amyloid Deposition in Cognitively Normal Older Adults. <b>2019</b> , 74, 1141-1148	5
711	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. <b>2019</b> , 11, 72	11
710	$\beta$ Amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <b>2019</b> , 9, 11180	15
709	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid $\beta$ Associated Cognitive Decline in Older Adults. <b>2019</b> , 34, 585-598	11
708	Added value of amyloid PET in individualized risk predictions for MCI patients. <b>2019</b> , 11, 529-537	6
707	Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology. <b>2019</b> , 15, 1160-1171	7
706	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. <b>2019</b> , 15, 501-518	322
705	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. <b>2019</b> , 11, 66	42
704	Medial temporal lobe atrophy and posterior atrophy scales normative values. <b>2019</b> , 24, 101936	8
703	Neuropsychological latent classes at enrollment and postmortem neuropathology. <b>2019</b> , 15, 1195-1207	7

702	Epidemiology of Vascular Dementia. <b>2019</b> , 39, 1542-1549	84
701	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. <b>2019</b> ,	106
700	Association of apolipoprotein E genotypes with epilepsy risk: A systematic review and meta-analysis. <b>2019</b> , 98, 27-35	5
699	Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum. <b>2019</b> , 70, 965-981	10
698	Can Subjective Memory Complaints Identify A $\beta$ Positive and A $\beta$ Negative Amnesic Mild Cognitive Impairment Patients?. <b>2019</b> , 70, 1103-1111	3
697	Is brain connectome research the future frontier for subjective cognitive decline? A systematic review. <b>2019</b> , 130, 1762-1780	13
696	Evidence of parietal hyperactivation in individuals with mild cognitive impairment who progressed to dementia: A longitudinal fMRI study. <b>2019</b> , 24, 101958	18
695	Lack of hepatic apoE does not influence early A $\beta$ deposition: observations from a new APOE knock-in model. <b>2019</b> , 14, 37	26
694	Apolipoprotein E $\epsilon$ allele effects on longitudinal cognitive trajectories are sex and age dependent. <b>2019</b> , 15, 1558-1567	10
693	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. <b>2019</b> , 11, 84	15
692	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. <b>2019</b> , 14, e0224030	13
691	Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis. <b>2019</b> , 10, 976	2
690	Prognostic plasma protein panel for A $\beta$ deposition in the brain in Alzheimer's disease. <b>2019</b> , 183, 101690	10
689	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <b>2019</b> , 86, 866-877	20
688	Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. <b>2019</b> , 72, 1119-1127	12
687	Cognition at age 70: Life course predictors and associations with brain pathologies. <b>2019</b> , 93, e2144-e2156	17
686	Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. <b>2019</b> , 93, e1474-e1484	23
685	Practical algorithms for amyloid $\beta$ probability in subjective or mild cognitive impairment. <b>2019</b> , 11, 180	4

684	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <b>2019</b> , 5, 597-609	26
683	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. <b>2019</b> , 9,	8
682	Targeting age-related differences in brain and cognition with multimodal imaging and connectome topography profiling. <b>2019</b> , 40, 5213-5230	18
681	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. <b>2019</b> , 71, 715-732	58
680	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. <b>2019</b> , 165, 63-106	4
679	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. <b>2019</b> , 11, 77	11
678	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <b>2019</b> , 15, 1478-1488	22
677	Do anti-amyloid- $\beta$ drugs affect neuropsychiatric status in Alzheimer's disease patients?. <b>2019</b> , 55, 100948	16
676	Interactive effect of age and APOE- $\epsilon$ allele load on white matter myelin content in cognitively normal middle-aged subjects. <b>2019</b> , 24, 101983	6
675	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <b>2019</b> , 11, 670-678	7
674	Amyloid- $\beta$ Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <b>2019</b> , 11, 7	27
673	The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice. <b>2019</b> , 67, 1235-1244	4
672	[Early detection of Alzheimer's disease and approaches for prevention]. <b>2019</b> , 62, 255-260	5
671	Is there a specific memory signature associated with A $\beta$ PET positivity in patients with amnesic mild cognitive impairment?. <b>2019</b> , 77, 94-103	7
670	Chronic Obstructive Pulmonary Disease and Risk of Dementia and Mortality in Lower to Middle Income Countries. <b>2019</b> , 70, S63-S73	3
669	Sex differences in Alzheimer's disease: Understanding the molecular impact. <b>2019</b> , 1719, 194-207	24
668	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <b>2019</b> , 138, 237-250	50
667	Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. <b>2019</b> , 6, 1113-1120	19

666	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. <b>2019</b> , 5, 216-227	51
665	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <b>2019</b> , 15, 1081-1103	10
664	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related $\beta$ Amyloid Status. <b>2019</b> , 76, 1060-1069	159
663	Latent Classes of Cognitive Functioning Among Depressed Older Adults Without Dementia. <b>2019</b> , 25, 811-820	5
662	Lifespan Intellectual Factors, Genetic Susceptibility, and Cognitive Phenotypes in Aging: Implications for Interventions. <b>2019</b> , 11, 129	18
661	Subthreshold amyloid and its biological and clinical meaning: Long way ahead. <b>2019</b> , 93, 72-79	27
660	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <b>2019</b> , 5, 164-174	9
659	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. <b>2019</b> , 15, 888-898	131
658	Association of Alzheimer's Disease Genetic Risk Loci with Cognitive Performance and Decline: A Systematic Review. <b>2019</b> , 69, 1109-1136	5
657	Traumatic Brain Injury as a Risk Factor for Dementia and Alzheimer Disease: Critical Review of Study Methodologies. <b>2019</b> , 36, 3191-3219	16
656	Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches. <b>2019</b> , 11, 95	9
655	Retinal layer thickness in preclinical Alzheimer's disease. <b>2019</b> , 97, 798-804	22
654	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <b>2019</b> , 11, 327-332	6
653	The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions. <b>2019</b> , 3, NS2018020310	10
652	Association of Anticholinergic Use with Incidence of Alzheimer's Disease: Population-based Cohort Study. <b>2019</b> , 9, 6802	13
651	APOE- $\epsilon$ risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. <b>2019</b> , 23, 101818	10
650	Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. <b>2019</b> , 8,	23
649	Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer's disease. <b>2019</b> , 9, 4966	8

648	The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. <b>2019</b> , 20,	18
647	Amyloid- $\beta$ PET Imaging in Aging and Dementia. <b>2019</b> , 119-129	
646	Is there a difference in regional read [F]lутemетamol amyloid patterns between end-of-life subjects and those with amnesіic mild cognitive impairment?. <b>2019</b> , 46, 1299-1308	9
645	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <b>2019</b> , 29, 2173-2182	19
644	CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. <b>2019</b> , 119, 445-452	13
643	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A $\beta$ 2, levels in non-demented elderly. <b>2019</b> , 79, 101-109	12
642	The incidence of mild cognitive impairment: A systematic review and data synthesis. <b>2019</b> , 11, 248-256	41
641	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <b>2019</b> , 22, 101786	13
640	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <b>2019</b> , 11, 180-190	46
639	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. <b>2019</b> , 68, 591-608	6
638	Association of Cognitive Function with Amyloid- $\beta$ and Tau Proteins in the Vitreous Humor. <b>2019</b> , 68, 1429-1438	13
637	A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease. <b>2019</b> , 68, 1625-1633	13
636	Characterizing the Molecular Architecture of Cortical Regions Associated with High Educational Attainment in Older Individuals. <b>2019</b> , 39, 4566-4575	9
635	Association Between Amyloid- $\beta$ Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. <b>2019</b> , 74, 1753-1760	6
634	Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative. <b>2019</b> , 68, 1549-1559	5
633	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1286-1294	27.4 223
632	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <b>2019</b> , 79, 50-58	22
631	The Effectiveness of Vitamin E Treatment in Alzheimer's Disease. <b>2019</b> , 20,	55

630	Stress and Alzheimer's disease. <b>2019</b> , 126, 1155-1161	13
629	The Importance of the Validation of M/EEG With Current Biomarkers in Alzheimer's Disease. <b>2019</b> , 13, 17	22
628	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <b>2019</b> , 77, 58-65	9
627	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. <b>2019</b> , 149, 139-157	8
626	Increased cerebral blood volume in small arterial vessels is a correlate of amyloid-related cognitive decline. <b>2019</b> , 76, 181-193	8
625	GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies. <b>2019</b> , 15, 515-524	21
624	The Role of Biomarkers in Alzheimer's Disease Drug Development. <b>2019</b> , 1118, 29-61	40
623	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities. <b>2019</b> , 27, 991-1001	16
622	Dementia spectrum disorders: lessons learnt from decades with PET research. <b>2019</b> , 126, 233-251	17
621	. <b>2019</b> ,	1
620	The many ages of man: diverse approaches to assessing ageing-related biological and psychological measures and their relationship to chronological age. <b>2019</b> , 32, 130-137	6
619	Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities. <b>2019</b> ,	24
618	Geroscience and the challenges of aging societies. <b>2019</b> , 2, 132-134	14
617	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. <b>2019</b> , 72, 1193-1207 <sup>2</sup>	
616	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy. <b>2019</b> , 24, 102091	12
615	The H1 Haplotype Is a Risk Factor for Alzheimer's Disease in $\beta$ Non-carriers. <b>2019</b> , 11, 327	7
614	Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. <b>2019</b> , 32, 548-556	4
613	Increases and Decreases in Functional Brain Activation in Healthy Older Adults: The Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Healthy Older Adults. <b>2019</b> , 27, 1372-1374	



612	Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy. <b>2019</b> , 11, 95	9
611	A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET/CT: a visual analysis. <b>2019</b> , 40, 525-531	1
610	The Effect of Changing the Amyloid $\beta$ 2 Cut-off of Cerebrospinal Fluid Biomarkers on Alzheimer Disease Diagnosis in a Memory Clinic Population in Norway. <b>2019</b> , 33, 72-74	3
609	The use of back propagation neural networks and 18F-Florbetapir PET for early detection of Alzheimer's disease using Alzheimer's Disease Neuroimaging Initiative database. <b>2019</b> , 14, e0226577	9
608	Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease. <b>2019</b> , 179, 1736-1737	3
607	Clinical Use of Integrated Positron Emission Tomography-Magnetic Resonance Imaging for Dementia Patients. <b>2019</b> , 28, 299-310	6
606	Association of Longitudinal $\beta$ Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <b>2019</b> , 2, e1916439	10
605	Preventing Cognitive Decline and Dementia. <b>2019</b> , 291-306	1
604	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: information from discordant cases. <b>2019</b> , 11, 100	17
603	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <b>2019</b> , 73, 61-67	42
602	Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. <b>2019</b> , 73, 21-29	20
601	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <b>2019</b> , 97, 3-17	51
600	A critical appraisal of amyloid- $\beta$ targeting therapies for Alzheimer's disease. <b>2019</b> , 15, 73-88	387
599	The Synergistic Effects of APOE Genotype and Obesity on Alzheimer's Disease Risk. <b>2018</b> , 20,	22
598	Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa. <b>2019</b> , 269, 973-984	2
597	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. <b>2019</b> , 11, 7	39
596	Amyloid- $\beta$ immunotherapy for alzheimer disease: Is it now a long shot?. <b>2019</b> , 85, 303-315	87
595	Age Moderates the Effects of Traumatic Brain Injury on Beta-Amyloid Plaque Load in APP/PS1 Mice. <b>2019</b> , 36, 1876-1889	9

594	Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease. <b>2019</b> , 40, 65-84	46
593	Associations between tau, A $\beta$ and cortical thickness with cognition in Alzheimer disease. <b>2019</b> , 92, e601-e612	125
592	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <b>2019</b> , 15, 388-399	19
591	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <b>2019</b> , 40, 638-651	17
590	Accurate risk estimation of $\beta$ amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <b>2019</b> , 15, 194-204	31
589	Hypertension and obesity moderate the relationship between $\beta$ amyloid and cognitive decline in midlife. <b>2019</b> , 15, 418-428	19
588	In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies. <b>2019</b> , 74, 171-181	12
587	Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <b>2019</b> , 60, 541-547	33
586	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <b>2019</b> , 75, 42-50	26
585	Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer's disease in mild cognitive impairment patients. <b>2019</b> , 46, 288-296	13
584	Associations Between Positron Emission Tomography Amyloid Pathology and Diffusion Tensor Imaging Brain Connectivity in Pre-Clinical Alzheimer's Disease. <b>2019</b> , 9, 162-173	8
583	Cognitive Complaints in Memory Clinic Patients and in Depressive Patients: An Interpretative Phenomenological Analysis. <b>2019</b> , 59, 290-302	2
582	Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging. <b>2020</b> , 40, 288-297	16
581	The impact of social networks and $\beta$ on dementia among older adults: tests of possible interactions. <b>2020</b> , 24, 395-404	7
580	Optical coherence tomography angiography in preclinical Alzheimer's disease. <b>2020</b> , 104, 157-161	65
579	F-FIBT may expand PET for $\beta$ amyloid imaging in neurodegenerative diseases. <b>2020</b> , 25, 2608-2619	7
578	Linking APOE- $\beta$ , blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology. <b>2020</b> , 85, 96-103	24
577	Education as a Moderator of the Relationship Between Episodic Memory and Amyloid Load in Normal Aging. <b>2020</b> , 75, 1820-1826	6

576	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. <b>2020</b> , 75, 1609-1617	5
575	Isolated, Subtle Neurological Abnormalities in Mild Cognitive Impairment Types. <b>2020</b> , 47, 77-91	1
574	Loneliness Increases the Risk of All-Cause Dementia and Alzheimer's Disease. <b>2020</b> , 75, 919-926	51
573	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <b>2020</b> , 57, 86-98	23
572	Large-scale network dysfunction in vascular cognitive disorder supports connective diaschisis in advanced arteriosclerosis. <b>2020</b> , 27, 352-359	2
571	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <b>2020</b> , 12, 8	6
570	APOE in the normal brain. <b>2020</b> , 136, 104724	39
569	Biomarkers of Alzheimer Disease. <b>2020</b> , 5, 194-208	13
568	Amyloid burden and white matter hyperintensities mediate age-related cognitive differences. <b>2020</b> , 86, 16-26	9
567	Brain imaging measurements of fibrillar amyloid- $\beta$ burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE $\epsilon$ allele. <b>2020</b> , 16, 598-609	10
566	Amyloid- $\beta$ -independent regulators of tau pathology in Alzheimer disease. <b>2020</b> , 21, 21-35	176
565	Neuropsychological decline up to 20 years before incident mild cognitive impairment. <b>2020</b> , 16, 512-523	16
564	Sex difference in Alzheimer's disease: An updated, balanced and emerging perspective on differing vulnerabilities. <b>2020</b> , 175, 261-273	22
563	Linguistic profiles, brain metabolic patterns and rates of amyloid- $\beta$ biomarker positivity in patients with mixed primary progressive aphasia. <b>2020</b> , 96, 155-164	1
562	Longitudinal retinal layer changes in preclinical Alzheimer's disease. <b>2021</b> , 99, 538-544	6
561	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <b>2020</b> , 19, 951-962	95
560	Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. <b>2020</b> , 78, 989-1010	19
559	Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis. <b>2020</b> , 192, 111386	4

558	Predicting future rates of tau accumulation on PET. <b>2020</b> , 143, 3136-3150	25
557	Predicting amyloid status using self-report information from an online research and recruitment registry: The Brain Health Registry. <b>2020</b> , 12, e12102	1
556	Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment. <b>2020</b> , 12, e12106	2
555	Variants in and are associated with higher tau deposition. <b>2020</b> , 2, fcaa159	3
554	Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. <b>2020</b> , 182, 976-991.e19	164
553	Association of Odor Identification Ability With Amyloid- and Tau Burden: A Systematic Review and Meta-Analysis. <b>2020</b> , 14, 586330	4
552	Association of and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. <b>2021</b> , 96, e650-e661	20
551	Spatial Distribution of Tau and Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. <b>2021</b> , 96, 191-192	
550	A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. <b>2020</b> , 10,	4
549	Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. <b>2021</b> , 15, 1355-1363	2
548	Synergy between amyloid- and tau in Alzheimer's disease. <b>2020</b> , 23, 1183-1193	207
547	Distribution and clinical impact of apolipoprotein E4 in subjective memory impairment and early mild cognitive impairment. <b>2020</b> , 10, 13365	3
546	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <b>2020</b> , 95, e2065-e2074	1
545	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. <b>2020</b> , 61, 1413-1418	6
544	Use of Light Therapy for Insomnia in the Elderly: Role of Circadian Rhythm Disorders. <b>2020</b> , 6, 176-183	2
543	Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. <b>2020</b> , 95, e984-e994	7
542	Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences. <b>2020</b> , 77, 203-217	1
541	Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline. <b>2020</b> , 12, 228	5

540	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <b>2020</b> , 16, 1182-1195	48
539	Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load. <b>2020</b> , 6, e12046	2
538	Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. <b>2020</b> , 95, e2622-e2634	4
537	Increased variability in reaction time is associated with amyloid beta pathology at age 70. <b>2020</b> , 12, e12076	4
536	Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease. <b>2020</b> , 10,	3
535	Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study. <b>2020</b> , 34, 815-823	4
534	Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. <b>2020</b> , 88, 921-932	14
533	The Framing of "Alzheimer's Disease": Differences Between Scientific and Lay Literature and Their Ethical Implications. <b>2021</b> , 61, 746-755	6
532	Aging-Related Hypometabolism in the Anterior Cingulate Cortex of Cognitively Intact, Amyloid-Negative Seniors at Rest Mediates the Relationship between Age and Executive Function but Not Memory. <b>2020</b> , 1, tgaa020	1
531	Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects. <b>2020</b> , 78, 229-244	4
530	Brain Amyloid Burden and Resting-State Functional Connectivity in Late Middle-Aged Hispanics. <b>2020</b> , 11, 529930	5
529	Exploring a Cost-Efficient Model for Predicting Cerebral A $\beta$ Burden Using MRI and Neuropsychological Markers in the ADNI-2 Cohort. <b>2020</b> , 10,	
528	Risk Factors Predicting Amyloid PET Positivity in Patients with Mild Cognitive Impairment and Apolipoprotein E e3/e3 Genotypes. <b>2020</b> , 77, 1017-1024	1
527	Attempt to Predict A/T/N-Based Alzheimer's Disease Cerebrospinal Fluid Biomarkers Using a Peripheral Blood DNA Methylation Clock. <b>2020</b> , 4, 287-296	0
526	Synaptic Organizers in Alzheimer's Disease: A Classification Based on Amyloid- $\beta$ Sensitivity. <b>2020</b> , 14, 281	4
525	Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. <b>2020</b> , 15, 55	38
524	Amyloid PET imaging in clinical practice. <b>2020</b> , 20, 451-462	7
523	Timing is everything: tau imaging across stages of Alzheimer's disease. <b>2020</b> , 143, 2634-2636	0

522	Association between $\beta$ and A $\beta$ burden in patients with Alzheimer- and vascular-type cognitive impairment. <b>2020</b> , 95, e2354-e2365	0
521	Successful cognitive aging: What the oldest-old can teach us about resistance and resilience. <b>2020</b> , 95, 329-330	3
520	A second X chromosome contributes to resilience in a mouse model of Alzheimer's disease. <b>2020</b> , 12,	40
519	Effects of long-term sleep disruption on cognitive function and brain amyloid- $\beta$ burden: a case-control study. <b>2020</b> , 12, 101	3
518	Decreased Alpha Reactivity from Eyes-Closed to Eyes-Open in Non-Demented Older Adults with Alzheimer's Disease: A Combined EEG and [ $^{18}$ F]florbetaben PET Study. <b>2020</b> , 77, 1681-1692	1
517	Sex Differences in in vivo Alzheimer's Disease Neuropathology in Late Middle-Aged Hispanics. <b>2020</b> , 74, 1243-1252	5
516	Deep Learning-Based Estimation of Non-Specific Uptake in Amyloid-PET Images from Structural MRI for Improved Quantification of Amyloid Load in Alzheimer's Disease. <b>2020</b> ,	4
515	Contribution of iron and A $\beta$ to age differences in entorhinal and hippocampal subfield volume. <b>2020</b> , 95, e2586-e2594	5
514	Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders. <b>2020</b> , 77, 935-947	3
513	Sleep Disturbance Forecasts $\beta$ Amyloid Accumulation across Subsequent Years. <b>2020</b> , 30, 4291-4298.e3	36
512	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. <b>2020</b> , 20, 337	7
511	Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. <b>2020</b> , 11, 4571	23
510	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. <b>2020</b> , 10, 13583	1
509	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <b>2020</b> , 17, e1003289	15
508	Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort. <b>2020</b> , 77, 831-842	2
507	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- $\epsilon$ in middle-age cognitively unimpaired individuals from the ALFA study. <b>2020</b> , 225, 2331-2345	3
506	Revisiting the Amyloid Cascade Hypothesis: From Anti-A $\beta$ Therapeutics to Auspicious New Ways for Alzheimer's Disease. <b>2020</b> , 21,	42
505	Identification of Alzheimer's disease using a convolutional neural network model based on T1-weighted magnetic resonance imaging. <b>2020</b> , 10, 22252	16

504	Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor. <b>2020</b> , 12,	6
503	Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease. <b>2020</b> , 6, e12090	0
502	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <b>2020</b> , 28, 102504	5
501	Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and. <b>2020</b> , 12, e12127	3
500	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <b>2020</b> , 12, e12097	3
499	APOE $\epsilon/\epsilon$ homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. <b>2020</b> , 6, e12117	2
498	APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. <b>2020</b> , 12, 141	34
497	APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. <b>2020</b> , 15, 63	35
496	Extensive memory testing improves prediction of progression to MCI in late middle age. <b>2020</b> , 12, e12004	9
495	Sarcopenia: A Contemporary Health Problem among Older Adult Populations. <b>2020</b> , 12,	50
494	No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study. <b>2020</b> , 20, 174	14
493	Pre-Diabetes, but not Type 2 Diabetes, Is Related to Brain Amyloid in Late Middle-Age. <b>2020</b> , 75, 1241-1252	13
492	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <b>2020</b> , 74, 213-225	10
491	The implications of different approaches to define AT(N) in Alzheimer disease. <b>2020</b> , 94, e2233-e2244	34
490	Interaction of bone and brain: osteocalcin and cognition. <b>2021</b> , 131, 1115-1123	4
489	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <b>2020</b> , 12, 57	7
488	Insula and Amygdala Atrophy Are Associated With Functional Impairment in Subjects With Presbycusis. <b>2020</b> , 12, 102	8
487	Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?. <b>2020</b> , 19, 533-543	38

486	Depression-an underrecognized target for prevention of dementia in Alzheimer's disease. <b>2020</b> , 10, 160	47
485	Beneficial Effects of Brain Reserve on Cognition in Individuals with Subjective Cognitive Decline from the SILCODE Study. <b>2020</b> , 75, 1203-1210	1
484	APOE $\epsilon$ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <b>2020</b> , 12, 65	13
483	The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. <b>2020</b> , 12, 66	6
482	Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. <b>2020</b> , 16, 1054-1064	23
481	Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia. <b>2020</b> , 16, 1259-1267	9
480	Alleles and Diet in Brain Aging and Alzheimer's Disease. <b>2020</b> , 12, 150	31
479	Impact of APOE- $\epsilon$ carriage on the onset and rates of neocortical A $\beta$ amyloid deposition. <b>2020</b> , 95, 46-55	15
478	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. <b>2020</b> , 176, 677-683	6
477	Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span. <b>2020</b> , 16, 651-661	20
476	2020 Alzheimer's disease facts and figures. <b>2020</b> , 16, 391	984
475	APOE- $\epsilon$ Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <b>2020</b> , 30, 4110-4120	2
474	Epidemiology of neurological diseases in older adults. <b>2020</b> , 176, 642-648	15
473	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <b>2020</b> , 124, 594-602	7
472	Prediction of rapid amyloid and phosphorylated-Tau accumulation in cognitively healthy individuals. <b>2020</b> , 12, e12019	6
471	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <b>2020</b> , 139, 1025-1044	18
470	CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. <b>2020</b> , 95, e256-e267	8
469	To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. <b>2020</b> , 11, 1583-1602	16



468	A Novel Connectome-Based Electrophysiological Study of Subjective Cognitive Decline Related to Alzheimer's Disease by Using Resting-State High-Density EEG EGI GES 300. <b>2020</b> , 10,	7
467	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. <b>2020</b> , 94, 111-120	9
466	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. <b>2020</b> , 16, 1582-1590	7
465	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <b>2020</b> , 77, 632-642	36
464	Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study. <b>2020</b> , 17, e1003022	13
463	APOE4 moderates effects of cortical iron on synchronized default mode network activity in cognitively healthy old-aged adults. <b>2020</b> , 12, e12002	9
462	The European medical information framework: A novel ecosystem for sharing healthcare data across Europe. <b>2020</b> , 4, e10214	6
461	Depressive Symptoms in the Elderly-An Early Symptom of Dementia? A Systematic Review. <b>2020</b> , 11, 34	22
460	Impairment of PGC-1 $\beta$ -mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer's pathology in the 3xTg mouse model of Alzheimer's disease. <b>2020</b> , 133, 110882	20
459	Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. <b>2020</b> , 10, 2138	1
458	Morphometric network differences in ageing versus Alzheimer's disease dementia. <b>2020</b> , 143, 635-649	14
457	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. <b>2020</b> , 73, 1647-1659	3
456	Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia: A Systematic Review With Meta-analysis. <b>2020</b> , 157, 1538-1558	15
455	Accelerated brain aging towards transcriptional inversion in a zebrafish model of the K115fs mutation of human PSEN2. <b>2020</b> , 15, e0227258	13
454	Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches. <b>2020</b> , 21,	40
453	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. <b>2020</b> , 11, 667	113
452	Effect of the ZiBuPiYin Recipe on Diabetes-Associated Cognitive Decline in Zucker Diabetic Fatty Rats After Chronic Psychological Stress. <b>2020</b> , 11, 272	4
451	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <b>2020</b> , 177, 113945	26

450	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <b>2020</b> , 77, 735-745	81
449	The A4 study: $\beta$ Amyloid and cognition in 4432 cognitively unimpaired adults. <b>2020</b> , 7, 776-785	15
448	Amyloid $\beta$ Influences the relationship between cortical thickness and vascular load. <b>2020</b> , 12, e12022	4
447	[Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations]. <b>2020</b> , 91, 832-842	2
446	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <b>2020</b> , 93, 1-15	6
445	Association between retinal thickness and $\beta$ Amyloid brain accumulation in individuals with subjective cognitive decline: FundaciACE Healthy Brain Initiative. <b>2020</b> , 12, 37	9
444	Amyloid Positivity as a Risk Factor for Memory Decline and Lower Memory Performance as an Indicator of Conversion to Amyloid Positivity: Chicken and Egg. <b>2020</b> , 87, 782-784	1
443	Associations of the Rate of Change in Geriatric Depression Scale with Amyloid and Cerebral Glucose Metabolism in Cognitively Normal Older Adults: A Longitudinal Study. <b>2021</b> , 280, 77-84	1
442	Middle-age dementia risk scores and old-age cognition: a quasi-experimental population-based twin study with over 20-year follow-up. <b>2021</b> , 92, 323-330	1
441	Visual interpretation of [ $^{18}$ F]Florbetaben PET supported by deep learning-based estimation of amyloid burden. <b>2021</b> , 48, 1116-1123	6
440	Trait anxiety, a personality risk factor associated with Alzheimer's Disease. <b>2021</b> , 105, 110124	4
439	Association Between Apolipoprotein E $\epsilon$ 4 vs $\epsilon$ 3, Age, and $\beta$ Amyloid in Adults Without Cognitive Impairment. <b>2021</b> , 78, 229-235	10
438	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- $\beta$ negative cognitively normal individuals. <b>2021</b> , 97, 41-48	12
437	Metabolic syndrome and its components in relation to in vivo brain amyloid and neurodegeneration in late middle age. <b>2021</b> , 97, 89-96	4
436	Iron Accumulation, Not $\beta$ Amyloid or Brain Volumes, Is Linked to Cognition in Older Patients Who Are Nondemented. <b>2021</b> , 298, 363-364	
435	Quantitative Susceptibility Mapping of Brain Iron and $\beta$ Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults. <b>2021</b> , 298, 353-362	1
434	Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. <b>2021</b> , 133, 110995	13
433	Gene- and age-informed screening for preclinical Alzheimer's disease trials. <b>2021</b> , 17, 457-465	0

432	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <b>2021</b> , 79, 163-175	2
431	APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. <b>2021</b> , 20, 68-80	92
430	APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid. <b>2021</b> , 79, 511-530	4
429	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <b>2021</b> , 26, 429-442	70
428	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <b>2021</b> , 36, 324-333	9
427	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. <b>2021</b> , 79, 819-832	2
426	Risk of dementia in $\epsilon$ carriers is mitigated by a polygenic risk score. <b>2021</b> , 13, e12229	2
425	Brain health registry GenePool study: A novel approach to online genetics research. <b>2021</b> , 7, e12118	2
424	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <b>2021</b> , 3, fcab180	5
423	Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies. <b>2021</b> , 8, 503-512	
422	Major Surgery Affects Memory in Individuals with Cerebral Amyloid- $\beta$ Pathology. <b>2021</b> , 79, 863-874	4
421	Frontotemporal Lobar Degeneration. <b>2021</b> , 61-89	
420	The Role of Amyloid PET in Diagnosing Possible Transmissible Cerebral Amyloid Angiopathy in Young Adults with a History of Neurosurgery: A Case Series. <b>2021</b> , 50, 356-360	3
419	The association of APOE $\epsilon$ 4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. <b>2021</b> , 13, 5	9
418	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. <b>2021</b> , 367-412	
417	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <b>2021</b> , 13, 2	5
416	Amyloid- $\beta$ cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <b>2021</b> , 8, 348-358	3
415	White matter microstructure disruption in early stage amyloid pathology. <b>2021</b> , 13, e12124	2

- 414 PET and SPECT Imaging of Neurodegenerative Diseases. **2021**, 1309-1334
- 413 Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. **2021**, 13, e12216 1
- 412 Dementia or no dementia in the elderly. Why?. **2021**, 115-126
- 411 Apolipoprotein E4 effects on topological brain network organization in mild cognitive impairment. **2021**, 11, 845 1
- 410 Head-to-head comparison of amplified plasmonic exosome A $\beta$ 2 platform and single-molecule array immunoassay in a memory clinic cohort. **2021**, 28, 1479-1489 4
- 409 Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. **2021**, 13, e12131 0
- 408 Improved amyloid burden quantification with nonspecific estimates using deep learning. **2021**, 48, 1842-1853 8
- 407 Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility. **2021**, 1281, 93-112 0
- 406 Fine Particulate Matter and Markers of Alzheimer's Disease Neuropathology at Autopsy in a Community-Based Cohort. **2021**, 79, 1761-1773 2
- 405 Role of Retinal Amyloid- $\beta$  in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. **2021**, 22, 8
- 404 Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. **2021**, 96, e1491-e1500 5
- 403 Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. **2021**, 2, CD010945 4
- 402 Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761 $\square$ ) in Patients with Amnesic Mild Cognitive Impairment. **2021**, 20, 378-384 4
- 401 Time between milestone events in the Alzheimer's disease amyloid cascade. **2021**, 227, 117676 5
- 400 Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals. **2021**, 79, 1801-1811 4
- 399 Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia. **2021**, 11, 4168 2
- 398 An optimized MRI and PET based clinical protocol for improving the differential diagnosis of Geriatric Depression and Alzheimer's Disease.
- 397 Intranasal drug delivery for treatment of Alzheimer's disease. **2021**, 11, 411-425 6

396	Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers. <b>2021</b> , 2, e58-e59	0
395	Olfactory Identification in Subjective Cognitive Decline: A Meta-Analysis. <b>2021</b> , 79, 1497-1507	3
394	Differential associations of APOE- $\epsilon$ and APOE- $\delta$ alleles with PET-measured amyloid- $\beta$ and tau deposition in older individuals without dementia. <b>2021</b> , 48, 2212-2224	6
393	Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer's Disease. <b>2021</b> , 21, 175-193	4
392	The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. <b>2021</b> , 22,	5
391	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <b>2021</b> , 9, 48	6
390	Ten Years of Research on Automatic Voice and Speech Analysis of People With Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review Article. <b>2021</b> , 12, 620251	11
389	HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition. <b>2021</b> , 35, 1403-1412	3
388	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <b>2021</b> , 89, 987-1000	5
387	Revealing Notch-dependencies in synaptic targets associated with Alzheimer's disease.	
386	Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. <b>2021</b> , 11, 6954	1
385	Investigating the Spatial Associations Between Amyloid- $\beta$ Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. <b>2021</b> , 80, 113-132	0
384	Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. <b>2021</b> , 1073858421997035	
383	Brain Molecular Connectivity in Neurodegenerative Conditions. <b>2021</b> , 11,	1
382	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer's Disease. <b>2021</b> , 10,	4
381	2021 Alzheimer's disease facts and figures. <b>2021</b> , 17, 327-406	474
380	Finding our way through the labyrinth of dementia biomarkers. <b>2021</b> , 48, 2320-2324	2
379	The Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. <b>2021</b> , 11, 455-474	16

378	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. <b>2021</b> , 18, 728-752	2
377	Recent advances in pre-clinical diagnosis of Alzheimer's disease. <b>2021</b> , 1	
376	Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer's disease. <b>2021</b> ,	5
375	Molecular Imaging of Neurodegenerative Parkinsonism. <b>2021</b> , 16, 261-272	
374	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <b>2021</b> , 13, 82	3
373	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. <b>2021</b> , 15, 630172	1
372	Increasing the confidence of F-Florbetaben PET interpretations: Machine learning quantitative approximation.. <b>2022</b> , 41, 153-163	
371	BigBrainWarp: Toolbox for integration of BigBrain 3D histology with multimodal neuroimaging.	2
370	Adherence to dietary guidelines and cognitive decline from middle age: the Doetinchem Cohort Study. <b>2021</b> , 114, 871-881	1
369	Neuronal loss and microgliosis are restricted to the core of A $\beta$ deposits in mouse models of Alzheimer's disease. <b>2021</b> , 20, e13380	4
368	Molecular Imaging of Extrapyrarnidal Movement Disorders With Dementia: The 4R Tauopathies. <b>2021</b> , 51, 275-285	2
367	KL*VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE*4 carriers. <b>2021</b> , 101, 123-129	4
366	The Effects of Amyloid and Tau on Functional Network Connectivity in Older Populations. <b>2021</b> , 11, 599-612	2
365	Subjective cognitive complaints at age 70: associations with amyloid and mental health. <b>2021</b> , 92, 1215-1221	2
364	MRI-based Alzheimer's disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer's disease. <b>2021</b> , 13, 13496-13514	3
363	Bundle-specific associations between white matter microstructure and A $\beta$ and tau pathology in preclinical Alzheimer's disease. <b>2021</b> , 10,	3
362	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. <b>2021</b> ,	7
361	Network interdigitations of Tau and amyloid-beta deposits define cognitive levels in aging. <b>2021</b> , 42, 2990-3004	2

360	Effects of amyloid pathology and the APOE $\epsilon$ allele on the association between cerebrospinal fluid A $\beta$ 8 and A $\beta$ 0 and brain morphology in cognitively normal 70-years-olds. <b>2021</b> , 101, 1-12	0
359	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <b>2021</b> ,	6
358	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <b>2021</b> , 27, 1034-1042	56
357	Imaging beta-amyloid (A $\beta$ )burden in the brains of middle-aged individuals with alcohol-use disorders: a [C]PIB PET study. <b>2021</b> , 11, 257	
356	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <b>2021</b> , 13, 624330	5
355	Differential associations of age and Alzheimer's disease with sleep and rest-activity rhythms across the adult lifespan. <b>2021</b> , 101, 141-149	4
354	Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease lead to depression?. <b>2021</b> , 17, 841-856	5
353	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <b>2021</b> , 20, 484-496	86
352	Digital Technology Differentiates Graphomotor and Information Processing Speed Patterns of Behavior. <b>2021</b> , 82, 17-32	3
351	Biological diagnosis of Alzheimer's disease and the issue of stigma. <b>2021</b> , 69, 195-207	1
350	Increased Glucose Activity in Subgenual Anterior Cingulate and Hippocampus of High Performing Older Adults, Despite Amyloid Burden. <b>2021</b> , 81, 1419-1428	1
349	Biomarkers for neurodegenerative diseases. <b>2021</b> , 27, 954-963	69
348	Pathological correlates of impaired self-awareness of memory function in Alzheimer's disease. <b>2021</b> , 13, 118	1
347	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <b>2021</b> , 12, 3825	9
346	Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cohort (PRO) SubStudy. <b>2021</b> , 11, e043114	1
345	[Neuropathology of dementia]. <b>2021</b> , 171, 257-273	
344	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. <b>2021</b> , 13, 113	2
343	Upwards Drift of Cerebrospinal Fluid Amyloid- $\beta$ 2 Over Twelve Years in a Consecutive Clinical Cohort. <b>2021</b> , 81, 1369-1373	2

342	Improving prediction of amyloid deposition in Mild Cognitive Impairment with a timed motor task.	
341	False Memory and Alzheimer's Disease Pathology in Patients with Amnesic Mild Cognitive Impairment: A Study with Amyloid PET. <b>2021</b> , 11, 172-180	0
340	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <b>2021</b> , 13, 133	6
339	Precocious White Matter Inflammation and Behavioural Inflexibility Precede Learning and Memory Impairment in the TgAPP21 Rat Model of Alzheimer Disease. <b>2021</b> , 58, 5014-5030	0
338	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. <b>2021</b> , 13, 132	0
337	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. <b>2021</b> , 97, e1017-e1030	3
336	The Burden of Alzheimer's Disease Mortality in the United States, 1999-2018. <b>2021</b> , 82, 803-813	4
335	Protective association of the $\epsilon/\epsilon$ heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men. <b>2021</b> , 17, 1779-1787	1
334	Volumetry of Olfactory Structures in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and a Meta-Analysis. <b>2021</b> , 11,	2
333	Customized Application of tDCS for Clinical Rehabilitation in Alzheimer's Disease. <b>2021</b> , 15, 687968	
332	Tau pathology mediates the effects of amyloid on neocortical tau propagation and neurodegeneration among individuals without dementia.	
331	Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults. <b>2021</b> , 103, 109-116	1
330	The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer's Disease: A Review Study. <b>2021</b> , 11,	1
329	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <b>2021</b> , 11, 14394	1
328	A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer's disease.	2
327	The BigBrainWarp toolbox for integration of BigBrain 3D histology with multimodal neuroimaging. <b>2021</b> , 10,	5
326	Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease. <b>2021</b> , 13, 718959	2
325	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. <b>2021</b> , 12, 694329	2



324	Association of Apolipoprotein E e4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <b>2021</b> , 78, 937-947	11
323	Canine Cognitive Dysfunction (CCD) scores correlate with amyloid beta 42 levels in dog brain tissue. <b>2021</b> , 43, 2379-2386	3
322	Diagnostic and Therapeutic Challenges. <b>2021</b> , 41, 1780-1785	
321	Cognitive Decline Assessment: A Review From Medical Imaging Perspective. <b>2021</b> , 13, 704661	0
320	Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer's disease?. <b>2021</b> , 116, 108-124	6
319	Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies. <b>2021</b> , 22,	7
318	Interaction of Exogenous Butyrylcholinesterase with $\beta$ Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain. <b>2021</b> , 18, 470-481	
317	Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. <b>2021</b> , 82, 1045-1054	1
316	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <b>2021</b> ,	63
315	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. <b>2021</b> , 78, 961-971	29
314	Should Canadian patients look forward to aducanumab for Alzheimer disease?. <b>2021</b> , 193, E1430-E1431	
313	Diagnosis and Treatment of Alzheimer's Disease:: An Update. <b>2021</b> , 7, 74-85	1
312	In Reply: Recommendation to Create New Neuropathological Guidelines for the Postmortem Diagnosis of Chronic Traumatic Encephalopathy. <b>2021</b> , 89, E336-E337	0
311	Tau pathology mediates age effects on medial temporal lobe structure. <b>2021</b> , 109, 135-144	1
310	Preoperative Anemia and Risk for Perioperative Neurocognitive Dysfunction in Cardiac Surgery Patients: A Retrospective Analysis. <b>2021</b> ,	0
309	Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. <b>2021</b> , 13, 150	2
308	Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid- $\beta$ <b>2021</b> , 1866, 158980	3
307	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <b>2021</b> , 84, 119-128	1

306	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. <b>2021</b> , 11,	0
305	The Janus-like Association between Proton Pump Inhibitors and Dementia. <b>2021</b> , 18, 453-469	1
304	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. <b>2021</b> , 10,	2
303	Inhibitory Effects of Six Types of Tea on Aging and High-Fat Diet-Related Amyloid Formation Activities. <b>2021</b> , 10,	5
302	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. <b>2021</b> , 11,	
301	F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum. <b>2021</b> , 1	2
300	Can platelet activation result in increased plasma A $\beta$ levels and contribute to the pathogenesis of Alzheimer's disease?. <b>2021</b> , 71, 101420	6
299	The prevalence of painful physical symptoms in major depressive disorder: A systematic review and meta-analysis of observational studies. <b>2021</b> , 111, 110372	0
298	Sex differences in neuroimaging biomarkers in healthy subjects and dementia. <b>2021</b> , 125-162	
297	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <b>2021</b> , 7, e12135	4
296	Disclosure of Diagnosis in MCI and Dementia. <b>2021</b> , 57-72	0
295	Behavioral Neurology. <b>2021</b> , 339-354	
294	In Vivo Two-Photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models. <b>2018</b> , 1750, 341-351	13
293	Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer's Disease. <b>2020</b> , 1260, 175-191	13
292	PET Neuroimaging in Dementia Conditions. <b>2021</b> , 211-282	2
291	Encyclopedia of Gerontology and Population Aging. <b>2020</b> , 1-8	2
290	Prevention of Alzheimer's Disease and Alzheimer's Dementia. <b>2016</b> , 1-26	1
289	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. <b>2020</b> , 469-504	3

288	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <b>2020</b> , 94, 71-80	7
287	Neuroimaging in Dementia. <b>2017</b> , 37, 510-537	34
286	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <b>2020</b> , 143, 3805-3815	18
285	Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. <b>2021</b> , 144, 434-449	21
284	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <b>2016</b> , 139, 2528-39	45
283	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <b>2020</b> , 2, fcaa177	3
282	Distinguishing Amnestic Mild Cognitive Impairment From HIV-Associated Neurocognitive Disorders. <b>2021</b> , 224, 435-442	3
281	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology.	3
280	Time between milestone events in the Alzheimer's disease amyloid cascade.	1
279	Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study.	1
278	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.	1
277	KL-VS heterozygosity is associated with reduced tau accumulation and lower memory impairment in Alzheimer's disease.	1
276	Accelerated brain aging towards transcriptional inversion in a zebrafish model of familial Alzheimer's disease.	2
275	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <b>2021</b> , 28, 2147-2155	7
274	Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. <b>2016</b> , 31, 205-215	16
273	Behavioral Variant Frontotemporal Dementia. <b>2019</b> , 25, 76-100	11
272	Beta-amyloid imaging in dementia. <b>2018</b> , 35, 1-6	5
271	Lower Ipsilateral Hippocampal Integrity after Ischemic Stroke in Young Adults: A Long-Term Follow-Up Study. <b>2015</b> , 10, e0139772	12

270	Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease. <b>2016</b> , 11, e0149056	6
269	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. <b>2018</b> , 13, e0191345	8
268	From Brain Disease to Brain Health: Primary Prevention of Alzheimer's Disease and Related Disorders in a Health System Using an Electronic Medical Record-Based Approach. <b>2017</b> , 4, 157-164	3
267	Short-Term Practice Effects and Amyloid Deposition: Providing Information Above and Beyond Baseline Cognition. <b>2017</b> , 4, 87-92	12
266	Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. <b>2019</b> , 6,	3
265	Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer's disease. <b>2020</b> , 12, 4407-4423	10
264	Low carotid wall shear stress independently accelerates the progression of cognitive impairment and white matter lesions in the elderly. <b>2018</b> , 9, 11402-11413	6
263	Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). <b>2015</b> , 6, 35284-303	57
262	Alzheimer's Disease Genetic Risk Factor APOE- $\epsilon$ 4 Also Affects Normal Brain Function. <b>2016</b> , 13, 1200-1207	44
261	Biomarkers for Alzheimer's Disease. <b>2019</b> , 16, 518-528	26
260	Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study. <b>2019</b> , 16, 633-649	1
259	Cognitive Reserve, Brain Reserve, APOE $\epsilon$ 4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. <b>2020</b> , 76, 249-260	5
258	Tau Protein-Targeted Therapies in Alzheimer's Disease: Current State and Future Perspectives. 69-82	1
257	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <b>2019</b> , 8,	27
256	Performance of Plasma Amyloid $\beta$ Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. <b>2021</b> , 13, 749649	2
255	Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. <b>2021</b> , 8, 2083-2092	1
254	Changes in brain activity related to episodic memory retrieval in adults with single domain amnesic mild cognitive impairment. <b>2021</b> , 166, 108208	0
253	Alzheimer's disease clinical trial update 2019-2021. <b>2021</b> , 1	6

252	Evaluation of a speech-based AI system for early detection of Alzheimer's disease remotely via smartphones.	0
251	Electroencephalography as a Non-Invasive Biomarker of Alzheimer's Disease: A Forgotten Candidate to Substitute CSF Molecules?. <b>2021</b> , 22,	1
250	Apolipoprotein E and Alzheimer's disease.. <b>2022</b> , 12, 496-510	1
249	A methodology for cohort harmonisation in multicentre clinical research. <b>2021</b> , 27, 100760	0
248	Cognitive reserve proxies, Alzheimer pathologies, and cognition. <b>2021</b> , 110, 88-95	2
247	Amyloid- $\beta$ PET Classification on Cognitive Aging Stages Using the Centiloid Scale. <b>2021</b> , 1	1
246	Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment. <b>2021</b> , 11,	0
245	Prevention of Alzheimer's Disease and Alzheimer's Dementia. <b>2017</b> , 549-574	
244	Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.	
243	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease.	1
242	Alzheimer's Disease. <b>2018</b> , 57-79	1
241	Extensive memory testing improves prediction of progression to MCI in late middle age.	
240	Respiratory disease and lower pulmonary function as risk factors for subsequent dementia: a systematic review with meta-analysis.	0
239	Targeting Age-Related Differences in Brain and Cognition with Multimodal Imaging and Connectome Topography Profiling.	0
238	Neural correlates of exceptional memory ability in SuperAgers: A multimodal approach using FDG-PET, PIB-PET, and MRI.	
237	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: Information from discordant cases.	
236	Genome-wide association study identifies affecting the rate of CSF A $\beta$ decline in non-demented elders. <b>2019</b> , 11, 5433-5444	3
235	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes.	0

- 234 Limitations of amyloid imaging in Alzheimer's disease. **2020**, 491-506
- 233 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 232 Bundle-specific associations between white matter microstructure and Aβ and tau pathology at their connecting cortical endpoints in older adults at risk of Alzheimer's disease.
- 231 . **2021**, 193, E1680-E1682
- 230 The protective impact of education on brain structure and function in Alzheimer's disease. **2021**, 21, 423 0
- 229 Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells. **2021**, 22, 1
- 228 Relationship of Sleep Quality and Cognitive Function in Patients with Mild Cognitive Impairment and Subjective Memory Impairment. **2020**, 17, 167-174
- 227 Deep Brain Stimulation for Alzheimer's Disease: Tackling Circuit Dysfunction. **2021**, 24, 171-186 9
- 226 Editorial: Searching for the Holy Grail Will Need Biomarkers. **2020**, 7, 4-6
- 225 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 224 Centenarians as Models of Resistance and Resilience to Alzheimer's Disease and Related Dementias. **2020**, 2, 3
- 223 Butyrylcholinesterase as a biomarker in Alzheimer's disease. **2020**, 263-280 0
- 222 Pathophysiology of Vascular Cognitive Impairment (II): Amyloid Contribution in Vascular Cognitive Impairment. **2020**, 87-97
- 221 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. **2020**, 6, e12098 0
- 220 Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. **2020**, 34, 357-359 1
- 219 A Meta-Analysis Study on Alzheimer's Disease.
- 218 APOE4 Copy Number-Dependent Proteomic changes in the Cerebrospinal Fluid.
- 217 Atrophy-centered subtyping of mild cognitive impairment.

216	Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer Disease Clinical Trial Recruitment. <b>2021</b> , 35, 141-147	0
215	Accuracy of Quantitative Positron Emission Tomography Assessment for Differentiating Cerebral Age-related from Pathological Amyloid Deposition: A Preliminary Report from a Case-series Study. <b>2018</b> , 17, 106-111	2
214	Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias. <b>2020</b> , 19, 34-45	
213	Is Aducanumab for LMICs? Promises and Challenges. <b>2021</b> , 11,	1
212	Boosting the diagnostic power of amyloid-PET using a data-driven spatially informed classifier for decision support. <b>2021</b> , 13, 185	
211	Aumento de la confianza en la interpretaci3n del PET con 18F-Florbetaben: Machine learning basado en la aproximaci3n cuantitativa. <b>2021</b> ,	
210	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer’s and Lewy Body Disease Spectra. <b>2021</b> , 15, 777706	2
209	A brain proteomic signature of incipient Alzheimer’s disease in young $\epsilon 4$ carriers identifies novel drug targets. <b>2021</b> , 7, eabi8178	2
208	Sex Differences in Alzheimer’s Disease Revealed by Free-Water Diffusion Tensor Imaging and Voxel-Based Morphometry. <b>2021</b> ,	1
207	Dementia risk reduction: why haven’t the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.. <b>2021</b> , 7, e12202	2
206	Alzheimer’s Disease. <b>2021</b> , 415-422	
205	Neurodegeneration/Demenz. <b>2021</b> , 200-208	
204	Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention.. <b>2022</b> , 9, 12-21	0
203	The Role of Apolipoprotein E $\epsilon 4$ in Early and Late Mild Cognitive Impairment. <b>2021</b> , 84, 472-480	0
202	Concomitant AD and DLB pathologies shape subfield microglia responses in the hippocampus.	
201	Accuracy of quantitative positron emission tomography assessment for differentiating cerebral age-related from pathological amyloid deposition: A preliminary report from a case-series study. <b>2018</b> , 17, 106	2
200	Heterogeneity in Alzheimer’s Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.. <b>2022</b> , 1	2
199	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. <b>2022</b> ,	3

198	The Outcome of Patients with Amyloid-Negative Amnesic Mild Cognitive Impairment.. <b>2022,</b>	
197	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <b>2022,</b>	9
196	Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment.. <b>2021,</b> 13, 802501	0
195	My Healthy Brain: Rationale and Case Report of a Virtual Group Lifestyle Program Targeting Modifiable Risk Factors for Dementia.. <b>2022,</b> 1	
194	Genetically identical twins show comparable tau PET load and spatial distribution.. <b>2022,</b>	1
193	Prevalence Rates of Amyloid Positivity-Updates and Relevance.. <b>2022,</b>	1
192	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach.. <b>2022,</b>	2
191	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. <b>2022,</b> 4, fcac017	2
190	Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs.. <b>2022,</b>	1
189	Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.. <b>2022,</b>	2
188	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A $\beta$ accumulation and plaque-related pathology in a mouse model of amyloidosis.. <b>2022,</b> 17, 13	2
187	Association of APOE $\epsilon$ 4 with cerebral gray matter volumes in non-demented older adults: the MEMENTO cohort study.. <b>2022,</b> 118966	1
186	An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease.. <b>2022,</b> 320, 111443	1
185	Deep residual inception encoder-decoder network for amyloid PET harmonization.. <b>2022,</b>	1
184	Approche clinique des troubles neurocognitifs des pathologies d $\acute{e}$ g $\acute{e}$ neratives. <b>2022,</b> 3, 57-57	
183	Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment.. <b>2022,</b> 4, fcac016	0
182	Alzheimer's disease - standard of diagnosis, treatment, care, and prevention.. <b>2022,</b>	0
181	A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?. <b>2022,</b>	1



180	Sulcal morphology as cognitive decline predictor in older adults with memory complaints.. <b>2022</b> , 113, 84-94	
179	Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns.. <b>2021</b> , 2, 100467	1
178	Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration. 1	
177	Men and women show partly distinct effects of physical activity on brain integrity.. <b>2022</b> , 14, e12302	0
176	Improving Prediction of Amyloid Deposition in Mild Cognitive Impairment With a Timed Motor Task.. <b>2022</b> , 37, 15333175211048262	0
175	Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.. <b>2022</b> ,	2
174	Clear-headed into old age: Resilience and resistance against brain aging - A PET imaging perspective.. <b>2022</b> ,	0
173	Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer's Disease.. <b>2022</b> , 10,	0
172	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. <b>2022</b> ,	24
171	The Assessment of Cognitive Reserve: A Systematic Review of the Most Used Quantitative Measurement Methods of Cognitive Reserve for Aging.. <b>2022</b> , 13, 847186	0
170	Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels.. <b>2022</b> ,	
169	APOE e2 vs APOE e4 dosage shows sex-specific links to hippocampus-default network subregion co-variation.	0
168	Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer's Dementia?: Applying the Method of Reflective Equilibrium for a Clinical Dilemma.. <b>2022</b> , 1	0
167	Brain oxygen extraction and neural tissue susceptibility are associated with cognitive impairment in older individuals.. <b>2022</b> ,	0
166	2022 Alzheimer's disease facts and figures.. <b>2022</b> ,	95
165	Tract-specific white matter microstructure alterations among young adult APOE ε4 carriers: A replication and extension study.	
164	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease.. <b>2022</b> ,	0
163	Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and Synuclein pathologies in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies.. <b>2022</b> , 10, 36	1

162	Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. <b>2022</b> , 14, 831807	1
161	Lower novelty-related locus coeruleus function is associated with A $\beta$ -related cognitive decline in clinically healthy individuals.. <b>2022</b> , 13, 1571	1
160	Aging the Brain: Multi-Region Methylation Principal Component Based Clock in the Context of Alzheimer's Disease.	0
159	Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.. <b>2022</b> ,	5
158	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age.. <b>2022</b> , 14, 811146	1
157	Frequency of preclinical Alzheimer's disease in Japanese clinical study settings: a meta-analysis.	
156	CSF biomarkers for dementia.. <b>2022</b> ,	0
155	Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants.. <b>2022</b> ,	2
154	Ethnic differences in the frequency of $\beta$ amyloid deposition in cognitively normal individuals.. <b>2022</b> , 114, 27-37	
153	The protective gene dose effect of the APOE $\epsilon$ allele on gray matter volume in cognitively unimpaired individuals. <b>2021</b> ,	4
152	Association between ambient temperature and cognitive function in a community-dwelling elderly population: a repeated measurement study. <b>2021</b> , 11, e049160	
151	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	0
150	Validation of Plasma Amyloid- $\beta$ 2/40 for Detecting Alzheimer Disease Amyloid Plaques.. <b>2021</b> ,	7
149	Characteristics of subjective cognitive decline associated with amyloid positivity. <b>2021</b> ,	2
148	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.. <b>2022</b> ,	
147	Table_1.PDF. <b>2018</b> ,	
146	Table_1.docx. <b>2018</b> ,	
145	Data_Sheet_1.docx. <b>2020</b> ,	

144 Table\_1.DOCX. **2018,**

143 Table\_2.docx. **2018,**

142 Table\_3.DOCX. **2018,**

141 Table\_4.DOCX. **2018,**

140 Data\_Sheet\_1.ZIP. **2018,**

139 Data\_Sheet\_2.docx. **2018,**

138 Data\_Sheet\_3.docx. **2018,**

137 Data\_Sheet\_4.docx. **2018,**

136 Table\_1.DOCX. **2019,**

135 DataSheet\_1.docx. **2020,**

134 Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.. **2022,** 2

133 Menopause status moderates sex differences in tau burden: a Framingham PET Study.. **2022,** ○

132 Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using the A4 Data.. **2022,** ○

131 Effects of age, amyloid, sex, and  $\beta$  on the CSF proteome in normal cognition.. **2022,** 14, e12286

130 Diagnostic Categorization and Neurocognitive Prediction Employing Neuroimaging Data Using Deep Learning in Alzheimer's Illness. **2022,** 202-223

129 Commentary: Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.. **2022,** 14, 895398

128 How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?. **2022,**

127 Functional Imaging for Neurodegenerative Diseases.. **2022,** 104121 ○

126	Docosahexaenoic acid enhances hippocampal insulin sensitivity to promote cognitive function of aged rats on a high-fat diet. <b>2022,</b>	0
125	Abnormal Dynamic Functional Networks in Subjective Cognitive Decline and Alzheimer's Disease.. <b>2022, 16, 885126</b>	0
124	Efficacy and Mechanism of Moxibustion Treatment on Mild Cognitive Impairment Patients: An fMRI Study Using ALFF. <b>2022, 15,</b>	0
123	MST1 mediates neuronal loss and cognitive deficits: A novel therapeutic target for Alzheimer's disease.. <b>2022, 102280</b>	2
122	A New Nomogram Model for Individualized Prediction of Cognitive Impairment in Patients with Acute Ischemic Stroke.. <b>2022, 31, 106515</b>	0
121	Recognizing common PET patterns in neurodegenerative dementia. 06-12	
120	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre-Mild Cognitive Impairment.. <b>2022,</b>	0
119	Medial temporal lobe structure, mnemonic and perceptual discrimination in healthy older adults and those at risk for mild cognitive impairment.	
118	Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. <b>2022, 14,</b>	0
117	Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.	
116	The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications.	1
115	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. <b>2022, 63, 13S-19S</b>	4
114	The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer's disease: an exploratory analysis. <b>2022, 14,</b>	2
113	A comparison of advanced semi-quantitative amyloid PET analysis methods.	0
112	Global estimates on the number of persons across the Alzheimer's disease continuum.	5
111	Cognitive changes in old age: how to know that we are aging normally and how to age successfully. <b>2021, 22, 21-26</b>	
110	Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer's Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden. 14,	1
109	Metabolic Reprogramming of Microglia Enhances Proinflammatory Cytokine Release through EphA2/p38 MAPK Pathway in Alzheimer's Disease. <b>2022, 1-15</b>	0

108	Alzheimer Disease. <b>2022</b> , 28, 648-675	0
107	Staging of Alzheimer's disease: past, present, and future perspectives. <b>2022</b> ,	1
106	Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. <b>2022</b> , 18, 401	2
105	Simplified Edinburgh and modified Boston criteria in relation to amyloid PET for lobar intracerebral hemorrhage. <b>2022</b> , 35, 103107	0
104	Genome Sequencing Variations in the Octodon degus, an Unconventional Natural Model of Aging and Alzheimer's Disease. 14,	
103	Genotypic effects of APOE- $\epsilon$ 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation.	0
102	Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. <b>2022</b> , 12, 996	1
101	Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.	
100	Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. 14,	0
99	Independent APOE4 knock-in mouse models display reduced brain APOE protein, altered neuroinflammation, and simplification of dendritic spines.	0
98	Cognitive and neuroimaging correlates of financial exploitation vulnerability in older adults without dementia: Implications for early detection of Alzheimer's disease. <b>2022</b> , 140, 104773	0
97	The neuroprotective effects of oxygen therapy in Alzheimer's disease: a narrative review. <b>2023</b> , 18, 57	0
96	Sex differences in neurological and psychiatric diseases. <b>2023</b> , 933-952	
95	Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-84.	0
94	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	4
93	Causal links among amyloid, tau, and neurodegeneration.	0
92	Neuropathology and cholinesterase expression in the brains of octogenarians and older. <b>2022</b> , 110065	0
91	The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.	7

90	Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer's disease. <b>2022</b> , 14, 5641-5668	0
89	An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.	2
88	Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. <b>2022</b> , 12,	0
87	Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease. <b>2022</b> , 14,	0
86	Relationships between educational attainment, hypertension, and amyloid negative subcortical vascular dementia: The brain-battering hypothesis. 16,	
85	Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.	1
84	Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment. <b>2022</b> , 1-7	
83	Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations. 16,	1
82	Sulforaphane Upregulates Cultured Mouse Astrocytic Aquaporin-4 Expression through p38 MAPK Pathway. <b>2022</b> , 2022, 1-13	
81	International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease.	
80	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.	
79	Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF- $\kappa$ B Signaling Pathways in $\beta$ Amyloid-Induced Alzheimer's Disease Models. <b>2022</b> , 27, 5035	0
78	Alzheimer's Drug PBT2 Interacts with the Amyloid $\beta$ 42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs. <b>2022</b> , 61, 14626-14640	1
77	Influence of genetic and cardiometabolic risk factors in Alzheimer's disease. <b>2022</b> , 81, 101723	1
76	Tract-specific differences in white matter microstructure between young adult APOE $\epsilon$ carriers and non-carriers: A replication and extension study. <b>2022</b> , 2, 100126	0
75	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. <b>2023</b> , 455-492	0
74	Trajectory of clinical symptoms in relation to amyloid chronicity. <b>2022</b> , 14,	0
73	Sex and gender differences in dementia. <b>2022</b> , 179-233	0

72	Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study. <b>2022</b> , 8,	0
71	Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study.	0
70	Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment. <b>2022</b> , 8,	0
69	Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals.	0
68	Predicting conversion of brain $\beta$ amyloid positivity in amyloid-negative individuals. <b>2022</b> , 14,	0
67	How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?.	0
66	Disrupted role of the connectivity between the locus coeruleus and the hippocampus in cognition of healthy, middle-aged individuals at risk of dementia: the PREVENT-Dementia study.	0
65	Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia. <b>2022</b> , 1-9	1
64	Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity. <b>2022</b> , 4,	0
63	Hypothesis review: Alzheimer's overture guidelines.	1
62	Biomarker in der Diagnostik kognitiver Störungen $\beta$ Empfehlungen der Swiss Memory Clinics. <b>2022</b> , 111, 738-744	0
61	Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals.	0
60	Fluctuation of depressive symptoms in cognitively unimpaired participants and the risk of mild cognitive impairment 5 years later: Results of the Heinz Nixdorf Recall study. 16,	0
59	Influence of Gender on Tau Precipitation in Alzheimer's Disease According to ATN Research Framework.	0
58	A remote speech-based AI system to screen for early Alzheimer's disease via smartphones. <b>2022</b> , 14,	0
57	Study Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study. <b>2022</b> , 21, 147	1
56	Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study. 14,	0
55	Amyloid- and tau PET scans predict clinical progression in cognitively unimpaired people.	0

54	Can dementia risk be reduced by following the American Heart Association's Life's Simple 7? A systematic review and dose-response meta-analysis. <b>2022</b> , 101788	1
53	Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.	1
52	Blcenter-AD: Harmonising Alzheimer's Disease cohorts using a common ETL tool. <b>2022</b> , 101133	0
51	Medial temporal lobe structure, mnemonic and perceptual discrimination in healthy older adults and those at risk for mild cognitive impairment. <b>2022</b> ,	1
50	A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson's disease. <b>2022</b> , 8,	2
49	Big Five, self-reported depression, and anxiety are predictive for Alzheimer's disease.	0
48	Dietary Supplemented Anthocyanin Reduced Serum Amyloid Beta Oligomers and Improved Cognitive Dysfunction Scores in Elderly Dogs. <b>2022</b> , 12, 12130	0
47	Effect of APOE $\epsilon$ genotype on amyloid- $\beta$ glucose metabolism, and grey matter volume in cognitively normal individuals and amnesic mild cognitive impairment.	0
46	Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers.	0
45	Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer's Disease. <b>2022</b> , 23, 15670	0
44	Update Amyloid-Bildgebung in der Diagnostik der Neurodegeneration. <b>2022</b> , 45, 256-265	0
43	Vitamin D Status Over Time and Cognitive Function in Norwegian Older Adults: A Prospective Cohort of the HUNT Study.	0
42	APOE alleles are associated with sex-specific structural differences in brain regions affected in Alzheimer's disease and related dementia. <b>2022</b> , 20, e3001863	0
41	Role of monomeric amyloid- $\beta$ on cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. <b>2023</b> , 187, 106631	0
40	APOE effects on regional tau in preclinical Alzheimer's disease. <b>2023</b> , 18,	0
39	Distinct disease mechanisms may underlie cognitive decline related to hearing loss in different age groups. jnp-2022-329726	0
38	Insoluble Cellular Prion Protein and Other Neurodegeneration-Related Protein Aggregates in the Brain of Asymptomatic Individuals. <b>2023</b> , 63-86	0
37	Plasma amyloid- $\beta$ 2/40 and APOE for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease.	0



- 36 How an Intergenerational Book Club Can Prevent Cognitive Decline in Older Adults: A Pilot Study. **2023**, 9, 233372142211500 ○
- 35 Heart failure decouples the precuneus in interaction with social cognition and executive functions. **2023**, 13, ○
- 34 Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. **2023**, 172, 107800 ○
- 33 Circadian disruption and sleep disorders in neurodegeneration. **2023**, 12, ○
- 32 CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum. **2023**, 2023, 1-9 ○
- 31 Cortical amyloid-beta burden is associated with changes in intracortical myelin in cognitively normal older adults. **2023**, 13, ○
- 30 Genetically identical twin-pair difference models support the amyloid cascade hypothesis. ○
- 29 The action of phosphodiesterase-5 inhibitors on  $\beta$ amyloid pathology and cognition in experimental Alzheimer’s disease: A systematic review. **2023**, 320, 121570 ○
- 28 Treatment of Alzheimer’s disease by microcapsule regulates neurotransmitter release via microfluidic technology. **2023**, 4, 183-192 ○
- 27 Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. **2023**, 13, ○
- 26 Characteristics of Subjective Cognitive Decline Associated with Alzheimer’s Disease Amyloid Pathology: Findings from The CABLE Study. **2023**, 92, 581-590 ○
- 25 The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768 ○
- 24 Cretan Aging Cohort-Phase III: Methodology and Descriptive Characteristics of a Long-Term Longitudinal Study on Predictors of Cognitive Decline in Non-Demented Elderly from Crete, Greece. **2023**, 11, 703 ○
- 23 Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment. **2023**, 15, ○
- 22 Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline. **2023**, 38, 153331752311600 ○
- 21 Beyond the amyloid cascade: An update of Alzheimer’s disease pathophysiology. **2023**, ○
- 20 The common marmoset as a model of neurodegeneration. **2023**, 46, 394-409 ○
- 19 Predicting Conversion from Subjective Cognitive Decline to Mild Cognitive Impairment and Alzheimer’s Disease Dementia Using Ensemble Machine Learning. **2023**, 1-16 ○

18	2023 Alzheimer's disease facts and figures. <b>2023</b> , 19, 1598-1695	1
17	Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease.	0
16	Disease associations Alzheimer's disease, schizophrenia, Parkinson's disease, autism, and cancer. <b>2023</b> , 95-145	0
15	Brain Changes in Diabetes and Cognitive Dysfunction. <b>2023</b> , 381-395	0
14	Tratamiento del deterioro cognitivo. <b>2023</b> , 13, 4382-4394	0
13	Cerebrolysin in the treatment of cognitive impairment. <b>2023</b> , 123, 20	0
12	NHANES 2011-2014 Reveals Decreased Cognitive Performance in U.S. Older Adults with Metabolic Syndrome Combinations. <b>2023</b> , 20, 5257	0
11	Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. <b>2023</b> , 15,	0
10	APOE and immunity: Research highlights.	0
9	Brain Amyloid in Sporadic Young Onset Alzheimer's Disease. <b>2023</b> , 7, 263-270	0
8	Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer's disease.	0
7	The dual and emerging role of physical exercise-induced TFEB activation in the protection against Alzheimer's disease.	0
6	Association of Caffeine Consumption and Brain Amyloid Positivity in Cognitively Normal Older Adults. <b>2023</b> , 1-11	0
5	Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease. 15,	0
4	18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population. <b>2023</b> , 1-10	0
3	The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models.	0
2	Genetic risk of late-onset Alzheimer's disease is associated with longitudinal loss of functional brain network segregation in middle-aged cognitively healthy individuals: The PREVENT-Dementia Study.	0
1	Antisaccadic eye movements in middle-aged individuals with a family history of Alzheimer's disease. 17,	0

